Formycon

Gedeon Richter Becomes Strategic Investor of Formycon

Hungary-headquartered specialty pharmaceutical company Gedeon Richter becomes a strategic investor of German biosimilars company Formycon via cash capital increase of 9.08% of Formycon’s share capital, which corresponds to €82.84 million.

Topics • Technology

Chances and Hurdles for Biosimilars

Top-Feature

INOSIM GmbH

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

SchüllerConsulting